Table 3.
Acute (≤90 days of MRgSBRT start) and late toxicity (>90 days of MRgSBRT start) at least possibly attributable to MRgSBRT for all patients (N = 99).
| Toxicity1 | Acute Toxicity2 | Late Toxicity2 | ||||
|---|---|---|---|---|---|---|
| Grade 3 | Grade 4 | Grade 5 | Grade 3 | Grade 4 | Grade 5 | |
| Clinical | ||||||
| Hepatic | 5 (5) | 0 (0) | 0 (0) | 5 (5) | 1 (1) | 0 (0) |
| Biliary | 5 (5) | 1 (1) | 0 (0) | 5 (5) | 0 (0) | 1 (1) |
| Gastrointestinal, Other | 5 (5) | 0 (0) | 1 (1) | 3 (3) | 1 (1) | 0 (0) |
| Biochemical | ||||||
| AST/ALT | 1 (1) | 1 (1) | N/A | 5 (5) | 5 (5) | N/A |
| ALP | 4 (4) | 1 (1) | N/A | 8 (8) | 0 (0) | N/A |
| Total bilirubin | 6 (6) | 0 (0) | N/A | 11 (11) | 0 (0) | N/A |
AST, Aspartate Transaminase; ALT, Alanine Transaminase; ALP, Alkaline Phosphatase.
1
Toxicity ≥ grade 3 (CTCAE V 5.0) in all patients. Toxicity reported includes acute (≤90 days of MRgSBRT start) and late toxicity (>90 days of MRgSBRT start) at least possibly attributable to MRgSBRT. 2Statistics presented: n (%).